"Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty.
We studied the in-hospital outcome of 138 consecutive patients who received abciximab as a "rescue" intervention for complicated coronary angioplasty in a high-risk clinical setting. "Rescue" treatment with abciximab was associated with clinical and angiographic success rates of 83% and 84%, respectively, whereas the risk of bleeding was higher in patients of low body weight.
Garbarz
E
E
Cardiology Department, Tenon Hospital, Paris, France.
Farah
B
B
Vuillemenot
A
A
André
F
F
Angioï
M
M
Machecourt
J
J
Bassand
J P
JP
Wolf
J E
JE
Danchin
N
N
Prendergast
B
B
Iung
B
B
Vahanian
A
A
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000000981:diagnostic imaging / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D011379:Prognosis; D012189:Retrospective Studies; D012449:Safety; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab